Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications

Area of Science:

• Oncology
• Genetics
• Dermatology

Background:

• Melanoma incidence is rising globally, presenting a significant oncological challenge.
• Historically resistant to drugs, melanoma treatment has advanced since 2011 with immunotherapy and targeted therapies.
• Advances in Next-Generation Sequencing (NGS) enable detailed molecular characterization for identifying therapeutic targets.

Purpose of the Study:

• To review the landscape of mutated non-BRAF skin melanoma.
• To identify potential therapeutic targets beyond BRAF mutations.
• To summarize the status of targeted therapies for frequently mutated genes in melanoma.

Main Methods:

• Analysis of 10 Next-Generation Sequencing (NGS) studies encompassing 992 melanoma samples.
• Focus on Whole-Exome Sequencing (WES) and Whole-Genome Sequencing (WGS) data.
• Identification of 33 established and candidate driver genes mutated in over 1.5% of samples.

Main Results:

• Only 1.1% of samples lacked coding mutations.
• 30% of samples harbored mutations in RAS genes (primarily NRAS).
• 70% of samples exhibited mutations outside of RAS genes, indicating novel therapeutic opportunities.

Conclusions:

• Significant potential for new targeted therapies exists in non-BRAF mutated melanoma.
• Ongoing clinical trials are investigating treatments for 33.3% of frequently altered genes.
• Molecular profiling is crucial for guiding personalized melanoma treatment strategies.